PF-Atlas › Clinical Trials › NCT06125327
SC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis
SC1011 · Phase 2
Registry ID
NCT06125327
Phase
Phase 2
Status
Recruiting
Drug / intervention
SC1011
Sponsor
Guangzhou JOYO Pharma Co., Ltd
Start
2023-06-06
Enrollment
210
Locations
1
About this trial
Evaluating Sufenidone (SC1011) in IPF patients for efficacy and safety. Includes screening, treatment, and follow-up, with FVC decline and health checks.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT06125327 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.